Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says

12:29 PM EDT, 09/08/2026 (MT Newswires) -- Biohaven (BHVN) is facing a quieter stretch for major drug catalysts, and limited patient data and regulatory uncertainty may keep the shares more range-bound, RBC Capital Markets said Tuesday in a report. Biohaven's recent Kv7 licensing deal strengthens its balance sheet and reduces spending, giving the company enough cash to operate into 2028, though the agreement also removes some of the near-term upside tied to the program, which RBC had previously been viewed as a key bridge to later clinical readouts, the report said. RBC still sees long-term potential in Biohaven's degrader drugs for Graves' disease and IgA nephropathy, though meaningful phase 3 results may not arrive until 2028 for Graves and 2029 or later for IgAN. Patient data remains limited, raising the risk profile for those trials, the report said. A possible refiling of troriluzole for spinocerebellar ataxia may deliver major upside, though the timing and likelihood of eventual US Food and Drug Administration approval remain unclear, the report said. RBC sees longer-term value in Biohaven's cancer programs and in taldefgrobep, though these opportunities may take time given competitive markets and the need for additional data. RBC downgraded Biohaven to sector perform from outperform and cut its price target on the stock to $19 from $23. Price: 15.03, Change: -0.66, Percent Change: -4.21